Population pharmacokinetic modeling of Sepantronium bromide (YM155), a small molecule survivin suppressant, in patients with non-small cell lung cancer, hormone refractory prostate cancer, or unresectable stage III or IV melanoma

Purpose Population pharmacokinetics (PK) of sepantronium bromide (YM155) was characterized in patients with non-small cell lung cancer, hormone refractory prostate cancer, or unresectable stage III or IV melanoma and enrolled in one of three phase 2 studies conducted in Europe or the U.S. Method Sep...

Descripción completa

Detalles Bibliográficos
Autores principales: Aoyama, Yumiko, Kaibara, Atsunori, Takada, Akitsugu, Nishimura, Tetsuya, Katashima, Masataka, Sawamoto, Taiji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2012
Materias:
Phase II Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3589632/
https://www.ncbi.nlm.nih.gov/pubmed/22892872
http://dx.doi.org/10.1007/s10637-012-9867-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3589632/
https://www.ncbi.nlm.nih.gov/pubmed/22892872
http://dx.doi.org/10.1007/s10637-012-9867-x

Ejemplares similares